Potkin 1997.
| Methods | Allocation: randomised (no futher description). Blindness: double (no further description). Duration: 28 days. Consent: not stated. Setting: multicentre. | |
| Participants | Diagnosis: schizophrenia. N=246. Age: 18‐66 years.* Sex: 96M, 50F.* History: not stated. Exclusions: not stated. | |
| Interventions | 1. Risperidone: 4 mg/day FD. N=163. 2. Risperidone: 8mg/day FD. 3. Placebo. N=83. | |
| Outcomes | Mental state: PANSS.
Adverse effects: various observed effects.
Leaving the study early. Unable to use ‐ Clinical improvement: mean reduction in PANSS (no SD). Adverse effects: ESRS (no SD). |
|
| Notes | Data taken from conference poster. * Numbers given for Age ‐ only 236 people. Sex ‐ only 146 people. | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment? | Unclear risk | B ‐ Unclear |